Elaia Partners

Elaia Partners is a Paris-headquartered venture firm with deep ties to European research institutions, focused on commercializing early-stage computing, life sciences, and digital innovation. The firm has built a reputation as a serious technical investor in the French and broader European ecosystem, with a portfolio that reflects a willingness to back complex science before commercial traction is established.

The healthcare thesis spans digital health, AI and machine learning applied to healthcare, and biotech, with a notable presence in computational and AI-native life sciences companies. The portfolio includes BIOPHTA among healthcare-relevant investments, illustrating Elaia’s appetite for early biotech alongside its better-known software franchise. The broader thesis treats research-institution partnerships as a sourcing edge, and many Elaia investments emerge from relationships with European universities and public research bodies.

The firm writes $1M to $5M checks across Pre-Seed, Seed, and Series A, which is the classic European seed-to-Series-A band. That positioning lets Elaia lead formation rounds and continue into the first institutional Series A, with follow-on capacity that supports a meaningful ownership stake over the life of the relationship. Geographic focus is France and broader Europe, with portfolio companies routinely expanding into US and global markets as they mature.

Team and specific partner names are not provided in the source data, and the LinkedIn listing is unconfirmed, so founders should engage through Elaia’s website and expect to be routed to the partner whose expertise aligns with the underlying technology or science. The firm’s research-institution sourcing model means deal flow often comes through academic relationships rather than open inbound channels.

Elaia’s approach is technical and patient. The firm is comfortable with deep tech timelines and willing to underwrite complex science before commercial proof points exist, but expects strong founding teams with the credibility to execute over multi-year horizons. Elaia is a strong fit for European deep tech and life sciences founders with research-institution connections who want a technically sophisticated lead investor. Founders running purely commercial software businesses without a research or technical edge may find the fund less of a structural match.